Literature DB >> 7862525

Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.

P De Isabella1, F Zunino, G Capranico.   

Abstract

A number of antitumor drugs including naphthalimides, a new class of intercalating agents, interfere with the DNA breakage-reunion activity of mammalian DNA topoisomerase II resulting in DNA cleavage stimulation. In this work, the sequence specificity of a lead compound of this series, amonafide, in stimulating DNA cleavage by murine topoisomerase II has been studied. Amonafide-stimulated cleavage intensity patterns were markedly different from those of other antitumor drugs by using pBR322 and SV40 DNAs. This drug had an unusually high site selectivity since about 60% of DNA cleavage was observed at only one site in pBR322 DNA, and at two sites in SV40 DNA. A total of ninety-four drug-stimulated sites were collected, and a statistical analysis of their sequences showed that amonafide highly prefers a cytosine, and excludes guanines and thymines instead, at position -1. A lower preference for an adenine at position +1 was also noted. In agreement with the statistical analysis, the DNA sequences of the three sites stimulated by amonafide at exceptionally high levels showed that the drug requirements of a cytosine (-1) and adenine (+1) were present in both the two strands. In addition, a particular feature of these prominent cleavage sites was the presence of an inverted repeat from position -3 to +7. Comparison of amonafide stimulation of DNA cleavage in oligonucleotides bearing base mutations at positions -2, -3 and/or +6, +7 suggested that DNA sequence, and not a putative cruciform structure, was critical for drug action. Moreover, the results showed that, for strong cleavage stimulation, the primary drug requirements at -1 and +1 positions were not sufficient and that the sequence 5'-WRC decreases A-3' (W, A or T; R, A or G) is required from -3 to +1 positions at both strands. The results suggest that the exceptionally high sequence specificity of amonafide is the result of optimal drug interactions with both the two enzyme subunits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7862525      PMCID: PMC306658          DOI: 10.1093/nar/23.2.223

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  30 in total

1.  Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.

Authors:  Y H Hsiang; J B Jiang; L F Liu
Journal:  Mol Pharmacol       Date:  1989-09       Impact factor: 4.436

Review 2.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

3.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

Authors:  F H Drake; J P Zimmerman; F L McCabe; H F Bartus; S R Per; D M Sullivan; W E Ross; M R Mattern; R K Johnson; S T Crooke
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

Review 4.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

5.  In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.

Authors:  B S Andersson; M Beran; M Bakic; L E Silberman; R A Newman; L A Zwelling
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

6.  Intercalative binding to DNA of antitumour drugs derived from 3-nitro-1,8-naphthalic acid.

Authors:  M J Waring; A González; A Jiménez; D Vázquez
Journal:  Nucleic Acids Res       Date:  1979-09-11       Impact factor: 16.971

7.  Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.

Authors:  M Bigioni; F Zunino; G Capranico
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

8.  Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei.

Authors:  Y Pommier; R E Schwartz; L A Zwelling; K W Kohn
Journal:  Biochemistry       Date:  1985-11-05       Impact factor: 3.162

9.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

Authors:  K M Tewey; T C Rowe; L Yang; B D Halligan; L F Liu
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

10.  Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions.

Authors:  Y Adachi; E Käs; U K Laemmli
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more
  5 in total

Review 1.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  Novel naphthalimide polyamine derivatives as potential antitumor agents.

Authors:  Robert Seliga; Martina Pilatova; Marek Sarissky; Viktor Viglasky; Martin Walko; Jan Mojzis
Journal:  Mol Biol Rep       Date:  2013-05-03       Impact factor: 2.316

3.  Anticancer activity expressed by a library of 2,9-diazaperopyrenium dications.

Authors:  Karel J Hartlieb; Leah S Witus; Daniel P Ferris; Ashish N Basuray; Mohammed M Algaradah; Amy A Sarjeant; Charlotte L Stern; Majed S Nassar; Youssry Y Botros; J Fraser Stoddart
Journal:  ACS Nano       Date:  2015-01-23       Impact factor: 15.881

4.  COMMD4 is a novel prognostic biomarker and relates to potential drug resistance mechanism in glioma.

Authors:  Zongheng Liu; Long Peng; Yidan Sun; Zhichao Lu; Bing Wu; Weichen Wang; Xiaomei Zhang; Haiyan Hao; Peipei Gong
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

5.  Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.

Authors:  Malgorzata N Drwal; Jessica Marinello; Stefano G Manzo; Laurence P G Wakelin; Giovanni Capranico; Renate Griffith
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.